PROCEPT BioRobotics Corp (PRCT) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, PROCEPT BioRobotics Corp's filing signal continuing positive.

PROCEPT BioRobotics Corporation is a surgical robotics company specializing in minimally invasive urologic surgery, with a primary focus on treating benign prostatic hyperplasia (BPH). The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which utilize a heat-free waterjet and image guidance to remove prostate tissue. Aquablation therapy, delivered by these systems, aims to provide effective, safe, and durable outcomes for BPH patients, independent of prostate size and surgeon experience. As of December 31, 2025, PROCEPT had an installed base of 912 robotic systems globally, with 718 in the United States. The company generates revenue from system sales and rentals, as well as from single-use disposable handpieces and related accessories.

Revenue is primarily generated from the sales and rentals of its robotic systems and the sale of accompanying single-use disposable handpieces and related accessories. Service and repair contracts also contribute to revenue.